Class: Expansion (390)
Methods of promoting osteogenesis
Patent Number: 7,268,139This patent covers the composition of matter for a small molecule inhibitor of p38 MAP kinase, as well as the use of these compounds for stimulation/acceleration of bone healing. Presumably since p38 is involved in inflammatory signaling, the inhibition of this pathway allows for regenerative activities to prevail, thus allowing healing unimpeded by inflammation...
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)
Patent Number: 7,368,115Pharmaceutical activation of stem cells is arguably the next major revolution in medicine. The current patent is assigned to a Canadian stem cell company, Stem Cell Therapeutics (TSX-V:SSS), which already has entered Phase II clinical trials with pharmaceutical activators of endogenous stem cells for the treatment of stroke. While the ongoing clinical work of Stem Cell Therapeutics involves...
Oral compositions for white blood cell activation and proliferation
Patent Number: 7,256,026This patent covers an "activated yeast" preparation that is useful for stimulating production of white blood cells. The activation of the yeast cells is described using various electromagnetic fields. Interestingly, the yeast may be orally administered for augmentation of white blood cell number and activity. This is particularly useful for the treatment of immune suppressed patients...
Telomerase reverse transcriptase fragments and uses thereof
Patent Number: 7,294,708Telomerase reverse transcriptase is an enzyme that transcribes the telomerase RNA component into telomeric DNA in order to replenish telomeric loss associated with cellular proliferation. The activity of telomerase is absent in most adult cells with the exception of stem cells and tumor cells. Accordingly, one possible method of blocking...
Compositions and treatments for myelosuppression by ex vivo activated immune cells
Patent Number: 7,332,158Failure/suppression of the hematopoietic can be a deadly consequence of over-aggressive administration of chemotherapeutics/radiotherapy. The global market for agents that stimulate hematopoiesis, particularly granulopoiesis is in the billions of dollars per year, as witnessed by the success of Amgen’s Neuopgen and Neulasta products. The current patent teaches a novel, and arguably more...
Stimulation of hematopoiesis by ex vivo activated immune cells
Patent Number: 7048922This patent covers a clinically applicable method of increasing hematopoiesis through administration of activated peripheral blood mononuclear cells. The ability of these cells to secrete hematopoietic stimulatory cytokines is well established, however the inventor is actually claiming a method of using such ex vivo activated cells for treatment of a patient. The patent has 1 independent...
Spinal fusion using an HMG-CoA reductase inhibitor
Patent Number: 7041309HMG-CoA reductase inhibitors ("Statins" for the purpose of our discussion) have been known to increase endothelial stem cell mobilization, as well as possess other interesting functions such as suppressing disease in the mouse model of multiple sclerosis. In this patent, the use of statins for promoting spinal fusion is thought. Specifically, the patent...
Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
Patent Number: 7,344,881This patent covers methods of expanding hematopoietic stem cells and their progenitors. The methods induce expansion but not differentiation of the cells. Essentially the patent teachs that expansion can be achieved by culture in media containing an "effective amount of TEPA-Cu chelate". TEPA stands for tetraethylenepentamine...
Serum-free media for chondrocytes and methods of use thereof
Patent Number: 7,169,610This patent discloses methods of expanding chondrocyte precursors and differentiated chondrocytes ex vivo without the use of animal derived tissue culture components. The patent teaches the use of growth factors such as platelet derived growth factor, together with specific lipids, such as stearic acid, myristic acid, oleic acid, linoleic acid, palmitic acid, palmitoleic acid...
Cytokine zcytor17 ligand
Patent Number: 7064186This is a composition of matter patent covering the cytokine zcytor17 ligand, which is involved in various immune and stem cell activities. The patent has 3 independent claims, all covering composition of matter. The email of the senior author is dillons@zgi.com